147 related articles for article (PubMed ID: 22864379)
1. VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation.
Marinova M; Lütjohann D; Breuer O; Kölsch H; Westhofen P; Watzka M; Mengel M; Stoffel-Wagner B; Hartmann G; Coch C; Oldenburg J
Eur J Clin Pharmacol; 2013 Mar; 69(3):467-75. PubMed ID: 22864379
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation.
Soedirman JR; De Bruijn EA; Maes RA; Hanck A; Grüter J
Br J Clin Pharmacol; 1996 Jun; 41(6):517-23. PubMed ID: 8799516
[TBL] [Abstract][Full Text] [Related]
3. The association between dietary vitamin K intake and serum undercarboxylated osteocalcin is modulated by vitamin K epoxide reductase genotype.
Nimptsch K; Nieters A; Hailer S; Wolfram G; Linseisen J
Br J Nutr; 2009 Jun; 101(12):1812-20. PubMed ID: 19025725
[TBL] [Abstract][Full Text] [Related]
4. Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status.
Crosier MD; Peter I; Booth SL; Bennett G; Dawson-Hughes B; Ordovas JM
J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):112-9. PubMed ID: 19436136
[TBL] [Abstract][Full Text] [Related]
5. A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption.
Jones KS; Bluck LJ; Wang LY; Coward WA
Eur J Clin Nutr; 2008 Nov; 62(11):1273-81. PubMed ID: 17671443
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of phylloquinone from an intravenous lipid emulsion.
Camilo ME; Jatoi A; O'Brien M; Davidson K; Sokoll L; Sadowski JA; Mason JB
Am J Clin Nutr; 1998 Apr; 67(4):716-21. PubMed ID: 9537619
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K1 concentration in breast-fed neonates after oral or intramuscular administration of a single dose of a new mixed-micellar preparation of phylloquinone.
Schubiger G; Tönz O; Grüter J; Shearer MJ
J Pediatr Gastroenterol Nutr; 1993 May; 16(4):435-9. PubMed ID: 8315554
[TBL] [Abstract][Full Text] [Related]
8. Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study.
Holzer G; Grasse AV; Zehetmayer S; Bencur P; Bieglmayer C; Mannhalter C
Transl Res; 2010 Jul; 156(1):37-44. PubMed ID: 20621035
[TBL] [Abstract][Full Text] [Related]
9. The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits.
Winn MJ; White PM; Scott AK; Pratt SK; Park BK
J Pharm Pharmacol; 1989 Apr; 41(4):257-60. PubMed ID: 2568466
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease.
Pereira SP; Rowbotham D; Fitt S; Shearer MJ; Wendon J; Williams R
J Hepatol; 2005 Mar; 42(3):365-70. PubMed ID: 15710219
[TBL] [Abstract][Full Text] [Related]
11. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.
Kovac MK; Maslac AR; Rakicevic LB; Radojkovic DP
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):558-63. PubMed ID: 20581661
[TBL] [Abstract][Full Text] [Related]
12. Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1.
Chatron N; Hammed A; Benoît E; Lattard V
Nutrients; 2019 Jan; 11(1):. PubMed ID: 30609653
[TBL] [Abstract][Full Text] [Related]
13. Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.
Nimptsch K; Rohrmann S; Nieters A; Linseisen J
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):49-56. PubMed ID: 19124480
[TBL] [Abstract][Full Text] [Related]
14. Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism.
Baek IH; Kang W; Yun HY; Lee SS; Kwon KI
J Clin Pharm Ther; 2011 Jun; 36(3):390-8. PubMed ID: 21545618
[TBL] [Abstract][Full Text] [Related]
15. Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding.
Pereira SP; Shearer MJ; Williams R; Mieli-Vergani G
Arch Dis Child Fetal Neonatal Ed; 2003 Mar; 88(2):F113-8. PubMed ID: 12598499
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
17. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
McDonald MG; Rieder MJ; Nakano M; Hsia CK; Rettie AE
Mol Pharmacol; 2009 Jun; 75(6):1337-46. PubMed ID: 19297519
[TBL] [Abstract][Full Text] [Related]
18. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.
Scibona P; Redal MA; Garfi LG; Arbelbide J; Argibay PF; Belloso WH
Genet Mol Res; 2012 Jan; 11(1):70-6. PubMed ID: 22290467
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
